23.11
-1.99%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Shanghai Fosun Pharmaceutical Group Co
Its shares trade on Shanghai under the ticker 600196.SS. It has been listed since 7 August 1998. In the fiscal year to 31 December 2025, it reported revenue of CN¥41.50bn and net income of CN¥3.37bn. At that date it held total assets of CN¥120.47bn and shareholders' equity of CN¥48.74bn.
Shanghai Fosun Pharmaceutical Group Co Ltd is a CN-based company operating in Pharmaceuticals industry. The company is headquartered in Shanghai, Shanghai. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a China-based company, principally engaged in the research and development, production and distribution of pharmaceuticals. The firm's products are mainly applied in the treatment of metabolism and digestive tract system, cardiovascular system, central nervous system, blood system, anti-tumor and anti-infection diseases. The firm is also engaged in medical equipment and medical diagnosis business, as well as the provision of medical services. The company distributes its products primarily in domestic and overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 7 Aug 1998
- Employees
- 31,370
- Website
- fosunpharma.com ↗
Leadership
Pay as last reported
- Mr. Yifang WuExecutive Chairman of the Board, since 2016CN¥12.0m
- Mr. Kexin WangExecutive Co-Chairman of the Board, since 2011CN¥15.1m
- Ms. Rongli FengExecutive President, Chief Human Resource Officer, Senior Vice PresidentCN¥3.9m
- Ms. Jing LiExecutive President, Senior Vice President, Chief Executive Officer - Mature Products & Manufacturing UnitCN¥4.0m
- Mr. Xingli WangExecutive President, Chief Executive Officer - Global R&D Center, CO-Chief Executive Officer - Innovative Drugs DivisionCN¥4.3m
- Mr. Wenjie ZhangExecutive President, Co-CEO - Innovative Drugs DivisionCN¥11.6m
- Mr. Deyong WenChief Executive Officer, Executive Director, since 2016CN¥9.8m
- Ms. Xiaohui GuanExecutive Vice Chairman of the Board, since 2016CN¥9.0m
- Mr. Zhanyu ChenChief Financial Officer, Senior Vice PresidentCN¥2.2m
- Mr. Qingui BaoSenior Vice President, Chairman of the Board - Medical Diagnostics UnitCN¥5.2m
- Mr. Hang HuSenior Vice PresidentCN¥3.0m
- Mr. Dongjiu LiSenior Vice PresidentCN¥3.4m
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 95
- Environment
- 99
- Social
- 99
- Governance
- 86
- Direct emissions (scope 1)
- 184,016 t
- Energy emissions (scope 2)
- 653,644 t
- Value chain emissions (scope 3)
- 91,775 t
- Women in the workforce
- 50.26752%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Shanghai Fosun Pharmaceutical Group Co Ltd possesses several key strengths that give it a competitive advantage:
Weaknesses
- Despite its strengths, Shanghai Fosun Pharmaceutical Group Co Ltd also faces certain weaknesses that need to be addressed:
Opportunities
- Shanghai Fosun Pharmaceutical Group Co Ltd can capitalize on the following opportunities to further enhance its growth prospects:
Threats
- Shanghai Fosun Pharmaceutical Group Co Ltd must be mindful of the following threats that could potentially impact its business:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.